相关实验视频
Updated: Jun 12, 2025

08:36
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
1.0K
博苏替尼用于治疗CML-安全使用它:播客
Jeffrey H Lipton1, Jorge E Cortes2
1Princess Margaret Cancer Centre, Toronto, ON, Canada.
Targeted oncology
|January 17, 2025
概括
博苏替尼有效治疗慢性髓性白血病 (CML) 在各种阶段和治疗线. 通过剂量调整来管理不良事件是优化CML患者博苏替尼治疗的关键.
科学领域:
- 血液学 血液学 血液学
- 药理学 药理学是指药理学的学科.
- 在瘤学瘤学.
背景情况:
- 博苏替尼是费城染色体阳性慢性髓性白血病 (Ph+ CML) 的第二代氨酸激酶抑制剂 (TKI).
- 它已被批准用于新诊断的Ph + CML以及对先前疗法耐药或不耐受的患者.
- 临床数据证实了博苏替尼在CML的第一线和后一线治疗设置中的有效性.
研究的目的:
- 要总结最近的博苏替尼布出版物.
- 讨论优化CML中博苏替尼治疗的策略.
- 审查博苏替尼的安全性概况和不良事件管理.
主要方法:
- 审查最近的博苏替尼出版物.
- 对临床试验数据关于疗效和安全性的分析.
- 讨论不良事件管理策略,包括剂量调整.
主要成果:
- 博苏替尼在各种CML患者群体和治疗线路中表现出有效性.
- 安全性概况包括胃肠道,血液学,肝脏和皮肤毒性.
- 剂量调整策略在管理博苏替尼的许多不良事件方面是有效的.
结论:
- 博苏替尼是Ph + CML的有效治疗选择.
- 了解和管理不良事件对于成功的长期博苏替尼治疗至关重要.
- 优化治疗包括仔细选择患者和积极管理毒性.
相关概念视频
Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
146
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
146
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K

